Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects by Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, Marie Alexandre, Séverine Guiu, Nelly Firmin, Stéphane Pouderoux, Marie Viala, Gerald Lossaint, Chloé Gautier, Caroline Mollevi, Matthieu Gracia, Celine Gongora, Litaty Mbatchi, Alexandre Evrard, William Jacot

Subjects: Get full text

Dual-Drug Delivery by Anisotropic and Uniform Hybrid Nanostructures: A Comparative Study of the Function and Substrate–Drug Interaction Properties by Delaram Kargari Aghmiouni, Sepideh Khoee

Get full text

SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug–drug interaction prediction by Jing Zhu, Chao Che, Hao Jiang, Jian Xu, Jiajun Yin, Zhaoqian Zhong

“…Abstract Background Drug–drug interactions (DDI) are prevalent in combination therapy, necessitating the importance of identifying and predicting potential DDI. …”
Get full text

Comparative Analysis, Structural Insights, and Substrate/Drug Interaction of CYP128A1 in <i>Mycobacterium tuberculosis</i> by Nokwanda Samantha Ngcobo, Zinhle Edith Chiliza, Wanping Chen, Jae-Hyuk Yu, David R. Nelson, Jack A. Tuszynski, Jordane Preto, Khajamohiddin Syed

Get full text

Risk of Adverse Drug-Drug Interactions in Heart Failure Patients with Co-morbidity Chronic Kidney Disease Prescribed Polypharmacy by Suryaman Aldi, Bakhriansyah Mohammad, Yustikasari Intan, Winata Nurikhwan Pandji, Laksono Adiputro Dwi

Subjects: Get full text

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer by Kaleem Anwar, PharmD, Lee Nguyen, PharmD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD, Alexandre Chan, PharmD, MPH

Subjects: “…Drug-drug interaction…”
Get full text

No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants by Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A‐Young Yang, Hyounggyoon Yoo, Yil‐Seob Lee, Anhye Kim

“…To validate the combination therapy of bersiporocin with pirfenidone or nintedanib, a randomized, open‐label, two‐part, one‐sequence, three‐period, three‐treatment study was designed to evaluate the effect of drug–drug interactions (DDI) regarding their pharmacokinetics, safety, and tolerability in healthy participants. …”
Get full text

TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens by Muellner, M, Duernberger, G, Ganglberger, F, Kerzendorfer, C, Uras, I, Schoenegger, A, Bagienski, K, Colinge, J, Nijman, S

“…Dataset 1 is a gene-drug interaction screen and is based on Luminex xMAP technology. …”

Retrospective cohort observation on psychotropic drug-drug interaction and identification utility from 3 databases: Drugs.com®, Lexicomp®, and Epocrates® by Ravi Pinkoh, Ratchanee Rodsiri, Sorawit Wainipitapong

“…The psychotropic drug-drug interaction (DDI) should be concerned and efficiently monitored by a proper instrument. …”
Get full text

Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model by Sung-Yoon Yang, Jin-Mu Yi, Jaemoo Chun, Seongwon Park, Tham Thi Bui, Hwi-Yeol Yun, Jung-Woo Chae, Mi-Kyung Jeong

Subjects: Get full text

Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021 by Cvetka Bačar Bole, Katja Nagode, Mitja Pišlar, Aleš Mrhar, Iztok Grabnar, Tomaž Vovk

Subjects: “…potential drug—drug interactions…”
Get full text

Drug Utilization and Potential Drug-Drug Interactions within an Intensive Care Unit at a University Tertiary Care Hospital in Egypt by Dima F. Obeid, Adel H. Karara

Subjects: Get full text

Prevalence and Predictors of Potential Drug-Drug Interactions in the Elderly: A Cross-Sectional Study in the Brazilian Primary Public Health System by Paulo Roque Obreli Neto, Alessandro Nobili, Srecko Marusic, Diogo Pilger, Camilo Molino Guidoni, André de Oliveira Baldoni, Joice Mara Cruciol-Souza, Alessandra Negri da Cruz, Walderez Penteado Gaeti, Roberto Kenji Nakamura Cuman

“…The primary objective of this study was to investigate the prevalence of clinically important potential drug-drug interactions (DDIs) in elderly patients attending the public primary health care system in Brazil. …”
Get full text

Simultaneous determination of moxifloxacin and H2 receptor antagonist in pharmaceutical dosage formulations by RP-HPLC: application to in vitro drug interactions by Najma Sultana, Mahwish Akhtar, Sana Shamim, Somia Gul, Muhammad Saeed Arayne

Get full text

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors by Dominique A. Garrison, Zahra Talebi, Eric D. Eisenmann, Alex Sparreboom, Sharyn D. Baker

Subjects: Get full text

Retrospective cohort observation on psychotropic drug-drug interaction and identification utility from 3 databases: Drugs.com®, Lexicomp®, and Epocrates®. by Ravi Pinkoh, Ratchanee Rodsiri, Sorawit Wainipitapong

“…The psychotropic drug-drug interaction (DDI) should be concerned and efficiently monitored by a proper instrument.…”
Get full text

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling by Karsten Menzel, Yuhsin Kuo, Dapeng Chen, Georgy Hartmann, Ying‐Hong Wang, Carolyn R. Cho, Jacqueline B. McCrea, Kazuhiko Asari

“…This PBPK model was further used to evaluate the drug interaction potential between letermovir and everolimus, an immunosuppressant that may be co‐administered with letermovir depending on regions. …”
Get full text

Risk of multiple drug interactions potentially linked to safety in patients receiving pangenotypic direct-acting antivirals for the treatment of Hepatitis C by J Mendez-Navarro, J Turnes, A García-Herola, R Morillo, M Méndez, M Rueda, C Hernández, A Sicras-Mainar

“…Introduction and Objectives: Previous studies have evaluated the risk of drug-drug interactions (DDI) in HCV patients receiving pangenotypic direct-acting antivirals (pDAA), but all are based on pairwise interaction. …”
Get full text

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling by Laura Maria Fuhr, Fatima Zahra Marok, Maximilian Mees, Felix Mahfoud, Dominik Selzer, Thorsten Lehr

Subjects: Get full text

Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project by Claudio Borghi, Alessia Ciancio, Ivan Gentile, Pasquale Perrone Filardi, Patrizio Pasqualetti, Stefano Brillanti

Subjects: Get full text